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Abstract
OBjECTIVE: To compare the correlations between
salivary alpha-amylase (sAA) activity and amylase,
alpha 1 (salivary) gene (AMY1) copy number or its
gene expression between splenic asthenia and
healthy children, and investigate the reasons of at-
tenuated sAA activity ratio before and after citric
acid stimulation in splenic asthenia children.
METHODS: Saliva samples from 20 splenic asthe-
nia children and 29 healthy children were collected
before and after citric acid stimulation. AMY1 copy
number, sAA activity, and total sAA and glycosylat-
ed sAA contents were determined, and their corre-
lations were analyzed.
RESULTS: Although splenic asthenia and healthy
children had no differences in AMY1 copy number,
splenic asthenia children had positive correlations
between AMY1 copy number and sAA activity be-
fore or after citric acid stimulation. Splenic asthenia
children had a higher sAA glycosylated proportion
ratio and glycosylated sAA content ratio, while
their total sAA content ratio and sAA activity ratio
were lower compared with healthy children. The
glycosylated sAA content ratio was higher than the
total sAA content ratio in both groups. Splenic as-
thenia and healthy children had positive correla-
tions between total sAA or glycosylated sAA con-
tent and sAA activity. However, the role played by
glycosylated sAA content in sAA activity in healthy
children increased after citric acid stimulation,
while it decreased in splenic asthenia children.
CONCLUSION: Genetic factors like AMY1 copy
number variations, and more importantly, sAA gly-
cosylation abnormalities leading to attenuated sAA
activity after citric acid stimulation, which were the
main reasons of the attenuated sAA activity ratio in
splenic asthenia children compared with healthy
children.
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INTRODUCTION
Salivary alpha-amylase (sAA) is an important compo-
nent of the salivary proteome. The protein is coded by
the AMY1 gene, and is synthesized and glycosylated in
the salivary glands. sAA is secreted into the oral cavity
under autonomic nerve control and contributes to
food digestion via the hydrolysis of starch to glucose
and maltose. Its activity significantly varies among indi-
viduals because of AMY1 copy number, sAA content
and glycosylation state, and neural regulation of sAA se-
cretion.1-4
In the 1980's, Pi-Wei Institute of Guangzhou Universi-
ty of Chinese Medicine found that the sAA activity ra-
tio before and after citric acid stimulation was signifi-
cantly lower in splenic asthenia patients compared with
healthy adults.5 This finding was verified in other stud-
ies.6-9 These results were included in the "Guiding Prin-
ciple of Clinical Research on New Drugs of Chinese
Medicine," published by the Ministry of Public Health
of PRC in 1993, and are used in clinical practice as a
reference index for the syndrome differentiation and
curative effect observation for splenasthenic syn-
drome.10 However, few reports have addressed the at-
tenuated sAA activity ratio in splenic asthenia patients.
In the present study, we aimed to investigate the associ-
ation between low sAA activity ratio and amylase, al-
pha 1 (salivary) gene (AMY1) copy numbers, and pro-
tein expression in splenic asthenia children before and
after citric acid stimulation.
MATERIALS ANDMETHODS
Study subjects
This study was approved by the Academic Ethics Com-
mittee of Guangdong Pharmaceutical University and
Haizhu Maternal and Child Health Hospital. All chil-
dren who participated were accompanied by parents or
guardians, and written informed consent was obtained
from patients and their guardians before study partici-
pation. Twenty splenic asthenia children (10 female
and 10 male) were recruited in the Haizhu Maternal
and Child health Hospital from April to November
of 2013. The mean age was (8 ± 2) years, ranging
from 5 to 12 years. Twenty-nine healthy children
(15 females and 14 males) were recruited within the
same time frame. The mean age of the healthy group
was (7 ± 3) years, ranging from 5 to 12 years. No
significant differences in sex or age were found be-
tween the two groups.
Diagnostic standard of splenic asthenia children
The diagnostic standard of splenasthenic syndrome is
outlined in the "Guiding Principle of Clinical Re-
search on New Drugs of Chinese Medicine" and from
clinical experience from the study authors' institute.5,10
The diagnostic standard of splenasthenic syndrome
was set up in "Guiding Principle of Clinical Research
on New Drugs of Chinese Medicine" and clinical expe-
rience gained at the authors'institute.5,10 The dominant
symptom items were (a) pale tongue proper with
thin-white coating; (b) poor appetite; (c) abdominal
distension; (d) loose stool or diarrhea. The secondary
iterms of symptoms were (a) emaciated; (b) feebleness;
(c) weak pulse. To make a diagnosis of splenasthenic
syndrome, the dominant item (a) is absolutely neces-
sary, and it should be combined with two of the other
three; or combined with one of the others and also ac-
companied by two or all three of the secondary items.
Inclusion and exclusion criteria of splenic asthenia
children
Patients were included if they: were clinically diag-
nosed with splenasthenic syndrome; were aged 5-
12 years; and both the splenic asthenia child and his or
her guardian gave informed consent. Patients were ex-
cluded if they: had a hypersensitive constitution, acute
infectious diseases, or psychosis; had severe primary dis-
ease or cardiovascular, cerebrovascular, liver, renal, or
hematopoietic systems; had dry mouth, salivary gland
disease, oral disease, neurogenic disease, or facial asym-
metry; or took any form of medication likely to inter-
fere with salivary secretion within 1 month.
Inclusion and exclusion criteria of healthy children
Healthy patients were included if they: were aged 5-
12 years; had no obvious diseases, and tongue and
pulse tracings were normal; and both the healthy child
and his or her guardian gave informed consent. Pa-
tients were excluded if they met any of the exclusion
criteria applied to the splenic asthenia children de-
scribed above.
Saliva sample collection
All saliva samples were collected in the morning be-
tween 9:00 and 11:00 am. Saliva collection was carried
out as previously described.11 Subjects were asked to re-
frain from eating or drinking anything other than wa-
ter for 1 h before sample collection. After sitting silent-
ly for 10 min, subjects were instructed to empty their
mouths by swallowing all saliva. Unstimulated (before
citric acid stimulation) saliva was obtained by passive
drooling into 5-mL test tubes over 3 min. Then, the
stimulated (after citric acid stimulation) saliva was ob-
tained by applying a 1×1-cm filter paper of citric acid
to the tongue for 1 min. While collecting the stimulat-
ed saliva, subjects were asked to raise their tongue tip
so that the citric acid from the filter paper did not in-
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terfere with the salivary pH value. All saliva samples
were frozen at ﹣ 20 ℃ until use. Upon thawing at
4 ℃ , the samples were centrifuged at 11 000 ×g, 4 ℃
for 10 min and the suspension was divided into ali-
quots and frozen at ﹣80 ℃ for total protein content,
sAA activity, and content analysis. The pellet was fro-
zen at﹣80℃ for DNA analysis.
sAA activity determination
sAA activity was determined by the EPS-G7 [4,6-ethyl-
idene (G7)-ρ-nitrophenyl (G1)-α, D-maltoheptaoside]
method, which is used to determinate pancreatic amy-
lase activity in clinic and was recommended by IFCC.12
Briefly, saliva samples were diluted 200 times before
sAA activity determination. The kinetic reaction assay
kit includes a specific chromogenic substrate, 4,6-ethyl-
idene-G7-ρ-nitrophenol, and the auxiliary enzymeα-glucosidase (KOFA Biotech Company, Guangzhou,
China). The substrate is cleaved by sAA and α-glucosi-
dase into ρ-nitrophenol (PNP), which has an absor-
bance peak at 405 nm (yellow). sAA activity was deter-
mined by measuring absorbance difference values of
PNP in 405 nm per unit time (ΔA/min), and is ex-
pressed as U/mL. sAA activity assay was performed in
the laboratory of the First Affiliated Hospital of Guang-
dong Pharmaceutical University.
sAA content determination
Western blot was used to determine sAA content ac-
cording to the methods of Perry et al.2 Briefly, total pro-
tein contents of all samples was determined using a
bicinchoninic acid (BCA) Protein Assay Kit (Beyotime,
Jiangsu, China). To quantify the sAA content in each
sample, a human sAA protein sample (Sigma, St. Lou-
is, MO, USA) of known quantity was run on each gel,
with 5-μg total protein of saliva for each sample. These
samples were resolved by SDS-PAGE, and were trans-
ferred onto a PVDF membrane (Roche, Basel, Switzer-
land). Membranes were blocked and incubated over-
night at 4 ℃ with primary antibodies raised against hu-
man salivary amylase (Abcam, Cambridge, Britain). Af-
ter washing in PBST, membranes were incubated in
secondary antibodies (R&D Systems, Minneapolis,
MN, USA). Membranes were washed again and ex-
posed to DAB substrate (TIANGEN Biotech, Bei-
jing, China). The Image Lab 4.1 software system
(Bio-Rad Laboratories, Inc., Berkeley, CA, USA) was
used for detection of the western blots. Quantifica-
tion of protein bands was performed using Gel-Pro
Analyzer 4.0 software (Media Cybernetics, Rochville,
MD, USA). The total and glycosylated sAA contents
were estimated using relative quantity of test sample
compared with human sAA protein sample of a
known quantity. The proportion of glycosylated sAA
content in total sAA content (glycosylated and
non-glycosylated sAA content) is expressed as the
sAA glycosylated proportion.
AMY1 copy number determination
The salivary pellet frozen at ﹣80 ℃ was resuspended
in 500-μL 0.01 mol/L phosphate buffered solution
(PBS) (Tianjin Fuchen Chemical Reagents Factory,
Tianjin, China). Then, the sample was centrifuged at
11 000 ×g for 5 min. The pellet was added to 50-μL
5 mol/L KI solution (Chengdu Kelong Chemical Re-
agent Factory, Chengdu, China) and vortexed for 30 s
to lyse the cells. The lysate was added to 100-μL 0.9%
NaCl solution (Tianjin Fuchen Chemical Reagents Fac-
tory) and 150-μL chloroform (Guangzhou Chemical
Reagents Factory, Guangzhou, China). Proteins were
precipitated after vortexing for 30 s and centrifugation
at 11 000 ×g for 5 min. The supernatant was added to
isopropanol (Chengdu Kelong Chemical Reagent Fac-
tory) of equal volume to precipitate the DNA. The
DNA pellet was washed once with 500-μL ethanol
(Guangzhou Chemical Reagents Factory) and dried at
room temperature. DNA was dissolved in 30-μL tris
(hydroxymethyl) aminomethane (Tris)-ethylenediami-
netetraacetic acid (EDTA) buffer (10-mM Tris, 1 mM
EDTA) (Tianjin Fuchen Chemical Reagents Factory),
and stored at﹣20℃ until use.
Real-time PCR was used to determine AMY1 copy
number as previously described.2 AMY1 gene amplifica-
tion primers were: F: 5′-GGAAGAATATAGATGC-
CAACCC-3′, R: 5′-TCAGCTGAACTGGATCATTT-
GT-3′ ; TP53 gene primers were: F: 5′-CCCTT
CCCAGAAAACCTACC-3′ , R: 5′-CAGGCATT-
GAAGTCTCATGG-3′. The PCR reaction system was
prepared according to the kit directions of iTaq Univer-
sal SYBR Green Supermix (Bio-Rad Laboratories, Inc.,
Berkeley, CA, USA), with 10-ng sample DNA tem-
plate. The thermal cycle temperature were as follows:
initial denaturation of 95 ℃ for 3 min, followed by 35
cycles of 95 ℃ for 15 s and 60 ℃ for 30 s, which was
run on a Bio-Rad CFX96 Touch Real-Time PCR Ma-
chine. Data were analyzed using CFX Manager Soft-
ware version 2.1 (Bio-Rad Laboratories, Inc., Berkeley,
CA, USA). AMY1 diploid copy number was estimated
using relative AMY1 quantity for test sample DNA, as
compared with the reference DNA sample
(NA18972; Coriell Cell Repositories, Camden, NJ,
USA), previously determined to have 14 AMY1 dip-
loid copies by qPCR and Fiber FISH.1,2 All samples
were run triplicate.
Statistical analysis
Statistical analysis and graphing were performed us-
ing GraphPad Prism 5.0 (GraphPad Software, Inc.,
LaJolla, CA, USA). Comparisons between splenic as-
thenia and healthy children were carried out using
unpaired t-test, and comparisons between stimulated
and unstimulated saliva samples were carried out us-
ing paired t-tests. Relationships between data sets
were analyzed using the Pearson correlation coeffi-
cient. A P value (two-tailed) of < 0.05 was consid-
ered significant.
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RESULTS
Comparisons of sAA activity, sAA content, and
AMY1 copy number between splenic asthenia and
healthy children
EPS-G7, western blot, and real-time PCR were used to
determine sAA activity, sAA content, and AMY1 copy
number, respectively. The determined results of twenty
splenic asthenia children and twenty-nine healthy chil-
dren are shown in Table 1. The sAA activity (t = 6.562,
P < 0.001), total sAA content (t = 3.483, P = 0.002),
and glycosylated sAA content (t = 3.140, P = 0.004) in
healthy children was significantly increased after citric
acid stimulation. However, only the sAA glycosylated
proportion significantly increased in splenic asthenia
children (t = 4.515, P < 0.001). Splenic asthenia chil-
dren had a higher sAA glycosylated proportion (t =
2.037, P = 0.0481) and lower sAA activity ratio (t =
2.112, P = 0.040) compared with healthy children. Ad-
ditionally, splenic asthenia children showed an increas-
ing or decreasing trend in glycosylated sAA content ra-
tio and total sAA content ratio (both P > 0.05). The
glycosylated sAA content ratio was higher than the to-
tal sAA content ratio in the two groups (healthy: t =
2.606, P = 0.016; splenic asthenia: t = 3.140, P =
0.006). No obvious differences in AMY1 copy num-
bers were found between splenic asthenia and healthy
children (t = 0.897, P = 0.375).
Correlation analysis between AMY1 copy number or
sAA content and sAA activity
The correlations between AMY1 copy number or sAA
content and sAA activity were analyzed and the results
are shown in Figures 1 and 2. The correlations can
help assess the role played by AMY1 copy number and
sAA protein expression in sAA activity before and after
citric acid stimulation between splenic asthenia and
healthy children.
For unstimulated and stimulated saliva from healthy
children, positive correlations were found between to-
tal sAA content and sAA activity (Figures 1A and 1B,
unstimulated: r = 0.499, P = 0.006; stimulated: r =
0.442, P = 0.016), while similar results were not found
between AMY1 copy number and sAA activity (Figure
1C, unstimulated: r = 0.006, P = 0.975; stimulated:
r = 0.073, P = 0.709). Low correlations were found be-
tween glycosylated sAA content and sAA activity (Fig-
ures 1A and B, unstimulated: r = 0.251, P = 0.188;
stimulated: r = 0.315, P = 0.096). The correlation coef-
ficient between glycosylated sAA content and sAA ac-
tivity increased 21% after citric acid stimulation, from
unstimulated 50% (0.251/0.499) to stimulated 71%
(0.315/0.442).
For unstimulated and stimulated saliva from splenic as-
thenia children, both total sAA content (unstimulated:
r = 0.507, P = 0.023; stimulated: r = 0.669, P = 0.001)
and glycosylated sAA content (unstimulated: r = 0.503,
P = 0.024; stimulated: r = 0.644, P = 0.002) had a pos-
itive correlation with sAA activity (Figure 2A and 2B).
The correlation coefficient between glycosylated sAA
content and sAA activity decreased 3% after citric acid
stimulation, from unstimulated 99% (0.503/0.507) to
stimulated 96% (0.644/0.669). There were positive
correlations between AMY1 copy number and stimulat-
ed sAA activity (unstimulated: r = 0.309, P = 0.185;
stimulated: r = 0.519, P = 0.019), and the correlation
coefficient between the two indexes in stimulated saliva
was higher than unstimulated saliva (Figure 2C).
DISCUSSION
The sAA protein is coded by the AMY1 gene on chro-
mosome 1p21. The AMY1 gene is one of the most
variable copy number variation (CNVs) loci in the hu-
man genome, with a reported range from 2 to 15 dip-
loid copies. Interestingly, Perry et al 2 found that indi-
viduals from populations that historically consumed a
high starch diet had significantly more copies of the
AMY1 gene than those populations who subsisted on a
protein-rich diet. In the present study, no significant
differences in AMY1 copy number were found be-
tween splenic asthenia and healthy children. However,
sAA indexe
sAA activity (U/mL)
Total sAA content (mg/mL)
Glycosylated sAA content
(mg/mL)
sAA glycosylated
proportionc
AMY1 copy number
Healthy children (n = 29)
Unstimulated
16.407±9.464
0.083±0.059
0.016±0.016
0.191±0.137
-
Stimulated
40.345±23.361a
0.158±0.158a
0.040±0.047a
0.231±0.098
7.847±2.697 -
Ratio
2.719±1.581
1.844±1.097
2.350±1.829
1.202±0.450
Splenic asthenia children (n = 20)
Unstimulated
26.810±34.048
0.142±0.217
0.025±0.038
0.166±0.085
-
Stimulated
36.450±38.744
0.186±0.287
0.053±0.086
0.247±0.072a
8.568±3.207 -
Ratio
1.867±1.044b
1.772±1.336
2.585±2.273
1.537±0.628b
Note: sAA: salivary alpha-amylase; AMY1: amylase, alpha 1 (salivary) gene. Student's paired t-test from before to after citric acid stimula-
tion within each group, aP < 0.05; Student's unpaired t-test from before to after citric acid stimulation between splenic asthenia and
healthy children, bP < 0.05; c: proportion of glycosylated sAA content in total sAA content.
Table 1 Salivary alpha-amylase (sAA) activity, sAA content, and amylase, alpha 1 (salivary) gene (AMY1) copy number between
splenic asthenia and healthy children ( xˉ ± s)
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the average AMY1 copy number from 49 Chinese chil-
dren was eight [(8.141 ± 3.146) copies, ranging from 1
to 15, 87% of individuals were between four and 12
copies], which was higher than the observations of Per-
ry et al.2 in populations with a high starch intake, at an
average of seven [(6.720 ± 2.351) copies, ranging from
1 to 14 copies, 85% of individuals were between three
and eight copies]. This finding suggests that Chinese
people with a high-starch diet might have more AMY1
copies. Additionally, study results in adults showed
unstimulated r = 0.006
stimulated r = 0.073
sA
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Figure 1 Correlation analysis between sAA content or AMY1
copy number and sAA activity in healthy children
A: correlation between total sAA content or glycosylated
sAA content and sAA activity in unstimulated saliva; B: corre-
lation between total sAA content or glycosylated sAA con-
tent and sAA activity in stimulated saliva; C: correlation be-
tween AMY1 copy number and sAA activity in unstimulated
and stimulated saliva. sAA: salivary alpha-amylase; AMY1:
amylase, alpha 1 (salivary) gene.
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Figure 2 Correlation analysis between sAA content or AMY1
copy number and sAA activity in splenic asthenia children
A: correlation between total sAA content or glycosylated
sAA content and sAA activity in unstimulated saliva. B: corre-
lation between total sAA content or glycosylated sAA con-
tent and sAA activity in stimulated saliva. C: correlation be-
tween AMY1 copy number and sAA activity in unstimulated
and stimulated saliva. sAA: salivary alpha-amylase; AMY1:
amylase, alpha 1 (salivary) gene.
sAA activity (U/mL)
sAA activity (U/mL)
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that AMY1 copy number was positively correlated
with sAA activity (r = 0.52),1 while similar reports were
not found in children. In the current study, we found
that there were positive correlations between AMY1
copy number and sAA activity in splenic asthenia chil-
dren, especially sAA activity after citric acid stimula-
tion (r = 0.519). However, similar results were not
found in healthy children. This result indicates that
the correlation between AMY1 copy number and sAA
activity are different between splenic asthenia and
healthy children, or children and adults. The reasons
might be related to salivary gland development and the
sAA protein expression process. Human salivary glands
are morphologically complete in utero, but their
growth continues in childhood by proliferation of
well-differentiated cells.13 Studies have shown that the
morphology of the oral mucosa, salivary gland func-
tion, and saliva composition change with age.14 Addi-
tionally, the sAA protein is coded by the AMY1 gene,
and sAA activity is influenced by its expression and se-
cretory processes in different physiological and patho-
logical conditions. Therefore, AMY1 copy number
play an important role in unstimulated and stimulated
sAA activity in splenic asthenia children, while no role
was found in healthy children.
sAA is secreted from the salivary glands mainly in re-
sponse to beta-adrenergic stimuli,15 which not only pro-
motes sAA secretion, but also induces increases in
N-linked protein glycosylation.4 sAA can be either gly-
cosylated or non-glycosylated in normal salivary glands
or the oral cavity. N-glycosylation levels also affect sAA
secretion, enzyme activity, and stability.3,16 Therefore,
total sAA content, and the proportion and content of
glycosylated sAA are important factors that influence
sAA activity. In the present study, splenic asthenia chil-
dren had a higher sAA glycosylated proportion ratio
and glycosylated sAA content ratio before and after cit-
ric acid stimulation, while their total sAA content ratio
and sAA activity ratio were lower compared with
healthy children. The glycosylated sAA content ratio
was higher than the total sAA content ratio in both
groups. This finding indicates that citric acid stimula-
tion increased the glycosylated sAA proportion and pro-
moted glycosylated sAA secretion, which further in-
creased total sAA content and raised sAA activity.
These effects may explain why sAA activity increases af-
ter citric acid stimulation. One study showed that gly-
cosylated sAA activity was higher than that of the
non-glycosylated protein.17 Further, glycosylated sAA is
more easily secreted. Therefore, an increase in the pro-
portion of glycosylated sAA not only promotes glyco-
sylated sAA content, but also rapidly increases sAA ac-
tivity. This is consistent with the universal law of rapid
response to stimulation. Our results indicate that the
sAA activity was not significantly different between
splenic asthenia and healthy children, while the sAA ac-
tivity ratio was lower in splenic asthenia children than
in healthy children. Before citric acid stimulation,
splenic asthenia children had higher total and glycosyl-
ated sAA content than healthy children, so their sAA
activity was higher. After citric acid stimulation, splen-
ic asthenia children had higher total and glycosylated
sAA content than healthy children, but their sAA activi-
ty was lower. These findings could be a result of sAA
glycosylation abnormalities after citric acid stimulation
in splenic asthenia children. Liu et al 18 found that the
N-glycosylation of total salivary glycoprotein and sAA
in splenic asthenia patients were incomplete after citric
acid stimulation. Therefore, incomplete sAA glycosyl-
ation in splenic asthenia children might be an impor-
tant factor leading to sAA activity attenuation after cit-
ric acid stimulation.
The glycosylated sAA proportion in splenic asthenia
children significantly increased after citric acid stimula-
tion (P < 0.05), and the glycosylated sAA proportion
ratio was higher in splenic asthenia children than
healthy children (P < 0.05). However, the glycosylated
sAA content and total sAA content in splenic asthenia
children saw no corresponding increase. We found that
the glycosylated sAA content in healthy children in-
creased 1.955 times (2.350/1.202) and total sAA con-
tent increased 1.534 times (1.844/1.202) after citric ac-
id stimulation, while the respective values in splenic as-
thenia children increased 1.682 times (2.585/1.537)
and 1.153 times (1.772/1.537). Therefore, splenic as-
thenia children had acute sAA secretion hypofunction
after citric acid stimulation. These results agree with
observed changes in sAA activity, total sAA content,
and glycosylated sAA content, all of which significantly
increased in healthy children after citric acid stimula-
tion. However, the increase was attenuated in splenic
asthenia children. Moreover, sAA is mainly controlled
by adrenergic nerves.15 Our results support the hypoth-
esis that splenic asthenia patients have adrenergic nerve
hypofunction and parasympathetic nervous hyperfunc-
tion.1,19 Therefore, splenic asthenia children have acute
sAA secretion hypofunction, and are unable to secrete
sufficient glycosylated and total sAA during citric acid
stimulation, which might be an important factor for
the observed attenuated sAA activity. Correlation analy-
sis between sAA content and sAA activity showed that
splenic asthenia and healthy children had positive cor-
relations between total or glycosylated sAA content
and sAA activity. However, the correlation coefficient
between glycosylated sAA content and sAA activity in-
creased 21% after citric acid stimulation in healthy
children, while it decreased 3% in splenic asthenia chil-
dren. This finding further indicates that sAA content
plays an important role in sAA activity, and explains
the role played by glycosylated sAA in sAA activity in-
creases in healthy children, but sAA activity decreases
in splenic asthenia children after citric acid stimula-
tion. This result is consistent with previous discus-
sion about incomplete sAA glycosylation and acute
sAA secretion hypofunction in splenic asthenia chil-
dren leading to attenuated sAA activity after citric ac-
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id stimulation.
Although no significant differences in sAA activity be-
fore and after citric acid stimulation were found be-
tween splenic asthenia and healthy children, the sAA
activity ratio was markedly lower in splenic asthenia
children than that in healthy children. This may be re-
lated to genetic factors like AMY1 copy number varia-
tion, and more importantly, abnormal sAA glycosyl-
ation and acute sAA secretion hypofunction leading to
attenuated sAA activity after citric acid stimulation.
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